Compare CDZI & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CDZI | PROK |
|---|---|---|
| Founded | 1983 | 2015 |
| Country | United States | United States |
| Employees | 31 | N/A |
| Industry | Water Supply | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 342.2M | 316.0M |
| IPO Year | N/A | 2021 |
| Metric | CDZI | PROK |
|---|---|---|
| Price | $3.01 | $1.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.40 |
| AVG Volume (30 Days) | ★ 1.3M | 1.1M |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $893,000.00 |
| Revenue This Year | $12.97 | N/A |
| Revenue Next Year | $102.40 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1075.00 |
| 52 Week Low | $2.87 | $1.45 |
| 52 Week High | $6.96 | $3.55 |
| Indicator | CDZI | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 35.92 | 40.15 |
| Support Level | N/A | $1.51 |
| Resistance Level | $5.08 | $2.59 |
| Average True Range (ATR) | 0.24 | 0.08 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 20.41 | 34.88 |
Cadiz Inc is a water solutions provider, dedicated to delivering clean, reliable, and affordable water for people. It provides water solutions with a combination of land, water, pipeline, and water filtration assets located in Southern California between key water systems serving population centers in the Southwestern United States. The company operates in two reportable segments; Land and Water Resources segment, comprises all activities regarding its properties in the eastern Mojave Desert, pre-revenue development of the Mojave Groundwater Bank (supply, storage, and conveyance), and agricultural operations; and the Water Filtration Technology segment, generating maximum revenue engaged in providing water filtration solutions for impaired or contaminated groundwater sources.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.